Qrons (QRON) Total Receivables: $0.00 Mil (As of Dec. 2024)


What is Qrons Total Receivables?

Qrons QRON Total Receivables is $0.00 Mil as of Dec. 2024.

Qrons's Total Receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.

Qrons Total Receivables Historical Data

* Premium members only.

The historical data trend for Qrons's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qrons Total Receivables Chart

Qrons Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Qrons Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Qrons Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Qrons (QRON) has a Total Receivables of $0.00 Mil as of Dec. 2024. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Qrons and its competitors.
Is Qrons' Total Receivables too high?
Qrons' current Total Receivables is $0.00 Mil.
How does Qrons' Total Receivables compare to GBLX and ENDV?
Qrons' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Qrons and its competitors. Qrons's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qrons stock overvalued right now?
Qrons (QRON) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Qrons (QRON), the current Total Receivables is $0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qrons Business Description

Address 611 N. Brand Boulevard, Suite 1300, Glendale, CA, USA, 91203
Qrons Inc. is a biotechnology company, dedicated to developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic-resistant bacteria, which is becoming the prominent and rapidly growing world-wide cause of illness and death. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM for treating concussions and other diffused axonal injuries.